BioSpace News Archive

Business

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the quarter ended September 30, 2023, and recent business highlights.

November 9, 2023
·
16 min read
Business

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights.

November 9, 2023
·
9 min read
Business

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, reported business updates and financial results for its third quarter ending September 30, 2023.

November 9, 2023
·
14 min read
BioMidwest

Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume

Daxor Corporation announces that Daxor was recently granted a patent for a system to provide remote blood volume monitoring after initial testing with Daxor BVA-100® diagnostic.

November 9, 2023
·
4 min read
BioMidwest

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Corp. announced that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis.

November 9, 2023
·
6 min read
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

PharmAbcine, Inc. announced that the Safety Review Committee has approved advancing to dose level 2 of the PMC-403 Phase 1 clinical study in neovascular age-related macular degeneration patients following completion of dose level 1 safety data evaluation.

November 9, 2023
·
4 min read
Business

Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.

November 9, 2023
·
14 min read
Biotech Beach

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

Maravai LifeSciences, Inc. scheduled to participate in the following investor conferences during the month of November.

November 9, 2023
·
1 min read
Business

Immunome Reports Third Quarter 2023 Financial Results

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

November 9, 2023
·
10 min read
Artivion Announces Completion of Enrollment in PERSEVERE Trial

Artivion, Inc. today announced that it has completed enrollment in the PERSEVERE clinical trial.

November 9, 2023
·
4 min read